Sign in
Taking people in United StatesPhase 4

Semaglutide Liquid Placed on the Tongue for Adults With Obesity

Tests semaglutide given as a liquid on the tongue in adults with obesity.

Key facts

Who runs it
Gila Therapeutics, Inc.
Where
Minneapolis, United StatesSee the site
Trial code
Registry title
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Status
Recruiting
Phase
Phase 4
People taking part
40 people, planned
Started
17 Jun 2026
Expected to end
May 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Semaglutide 6 mg liquid emulsion formulation
  • Wegovy® (semaglutide) Tablet
  • Placebo liquid emulsion formulation
Record updated
27 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity (body mass index 30 to 45) to test semaglutide given as a liquid on the tongue.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Obesity with a body mass index of 30 to 45.

Main reasons for not taking part

  • Type 2 diabetes mellitus
  • Multiple Endocrine Neoplasia Type 2
  • Medullary thyroid cancer

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Body Mass Index 30 to 45

Who cannot take part

  • Type 2 Diabetes Mellitus
  • Medullary thyroid cancer
  • Multiple Endocrine Neoplasia Type 2

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Clinical Research Institute of MinnesotaMinneapolis, United StatesContact: Gary D Berman, M.D.Taking people

About the trial

What the trial wants to find out

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

The 3 groups in the trial

  • Semaglutide liquid emulsion formulationTreatment being tested

    Semaglutide 6 mg liquid emulsion formulation daily

    Treatment: Semaglutide 6 mg liquid emulsion formulation

  • Placebo liquid emulsion formulationPlacebo, for comparison

    Placebo liquid emulsion formulation daily

  • Wegovy TabletExisting treatment, for comparison

    Wegovy (semaglutide) 25 mg Tablet daily after 90 day titration

    Treatment: Wegovy® (semaglutide) Tablet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity
Plain-language title
Semaglutide Liquid Placed on the Tongue for Adults With ObesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07728383, who can take part
Record updated
27 July 2026